The creator of Wegovy and Ozempic stated that this collaboration will leverage OpenAI’s technology to analyze intricate datasets, identify promising drug candidates, and enhance efficiency in manufacturing, distribution, supply chains, and corporate functions.
Pharmaceutical companies are increasingly adopting AI to optimize the more repetitive aspects of drug development, such as recruiting clinical trial participants, selecting sites, and preparing regulatory documents; however, industry leaders caution that the technology has not yet made significant strides in discovering major new molecules.
Novo is looking for innovative ways to reclaim its position in the increasingly competitive obesity-drug market against Indianapolis-based Lilly, which recently received US approval for its weight-loss medication Foundayo after Novo introduced oral Wegovy in January. Analysts predict that annual revenue from weight-loss drugs could surpass $100 billion in the coming decade.
Novo did not reveal the financial specifics of the agreement. It noted that pilot programs would launch across research and development, manufacturing, and commercial segments, with plans for full integration by the end of 2026.
Novo indicated that OpenAI would also assist in training its global workforce, enhancing AI literacy, and boosting productivity across various departments.
Training, Not Replacing
“The objective here is not to replace our scientists but to enhance their capabilities,” CEO Mike Doustdar said in an interview.
Doustdar emphasized that the partnership is not aimed at reducing Novo’s current workforce, but rather at improving productivity and moderating future hiring rates.
He mentioned that AI tools would enable employees to work more swiftly and effectively, lessening the need for significant team expansion moving forward. Following his appointment as CEO last year, Doustdar initiated a restructuring that resulted in the elimination of 9,000 jobs.
“AI is transforming industries, and in life sciences, it can contribute to longer and healthier lives,” stated OpenAI CEO Sam Altman. “This partnership with Novo Nordisk will facilitate accelerated scientific discoveries, improve global operations, and redefine patient care’s future.”
Novo highlighted that the partnership incorporates strict data protection measures, governance, and human oversight, building upon its existing AI initiatives with other tech partners and research organizations.
